Lucinactant for the prevention of respiratory distress syndrome in premature infants
| Autor: | Steven M. Donn, Brian K. Jordan |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Inflammation Bioinformatics Pulmonary surfactant medicine Humans Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Intensive care medicine Randomized Controlled Trials as Topic Respiratory Distress Syndrome Newborn Lung Respiratory distress business.industry Lucinactant Standard treatment Sinapultide Infant Newborn Proteins Phosphatidylglycerols Pulmonary Surfactants General Medicine Clinical trial Drug Combinations medicine.anatomical_structure Models Animal Fatty Alcohols medicine.symptom business Infant Premature |
| Zdroj: | Expert Review of Clinical Pharmacology. 6:115-121 |
| ISSN: | 1751-2441 1751-2433 |
| DOI: | 10.1586/ecp.12.80 |
| Popis: | Respiratory distress syndrome (RDS) is the leading cause of neonatal morbidity and mortality in premature infants. It is caused by surfactant deficiency and lung immaturity. Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis of clinical trials demonstrates that lucinactant is as effective as animal-derived surfactants in preventing RDS in premature neonates, and in vitro studies suggest it is more resistant to oxidative and protein-induced inactivation. Its synthetic origin confers lower infection and inflammation risks as well other potential benefits, which may make lucinactant an advantageous alternative to its animal-derived counterparts, which are presently the standard treatment for RDS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|